MedTrace Logo

The Effects of Treatment With Sertraline for Noncardiac Chest Pain

NCT01114100 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2010-05-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether care as usual or intervention (consisting of sertraline versus placebo), are effective in the treatment of panic disorder and/or depression driven noncardiac chest pain.

Conditions

Interventions

DRUG

sertraline

starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg

DRUG

placebo

patients received 1 pill, according to their complaints the number of pills was increased to maximally 3

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Adriaan Honig, Prof,MD,Phd · Now: St Lucas and Andreas Hospital, Amsterdam, Netherlands

  • Petra Kuijpers, MD, PhD · Maastricht University Medical Centre, Maastricht, the Netherlands

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114100 on ClinicalTrials.gov